This week in regulatory: 61 updates, +135% vs last week

The top regulatory developments of the week, ranked by significance

Collectively, these WHO updates may indicate that prequalification is broadening from a relatively narrow product-screening function into a more structured, systems-based pathway spanning diagnostics, devices, and adjacent quality frameworks. Sponsors should consider this a signal that global access strategies will increasingly depend on earlier evidence planning, tighter dossier readiness, and stronger alignment between product claims, analytical performance, and manufacturing controls. For RA, clinical ops, and QA, the priority should be to map where current development programs intersect with WHO prequalification expectations, especially for assay performance, device documentation, and supplier oversight. This could suggest a need to harmonize technical files, clinical evidence packages, and quality agreements sooner in development, because the operational burden may shift upstream even before formal submission.